Brain atrophy measured by MRI scans, positron emission tomography (PET) including imaging of amyloid burden, and CSF measurements including Aβ42 and total tau (t-tau) have been the prime candidate biosignatures for diagnosis and tracking disease progression. The gene discussed is MAPT; the disease is Brain atrophy.